Proteintech, a global leader in antibodies and life science solutions, is excited to announce additional product ...

Half-life in non-human primates (NHP) of more than 30 days, over three times longer than bimekizumab and expected to support a dose interval of two to three times per year Equivalent potency to bimeki ...

Half-life in non-human primates (NHP) of more than 30 days, over three times longer than bimekizumab and expected to support a dose interval of ...

New in vitro neutralization data show continued, consistent neutralizing activity of PEMGARDA™(pemivibart) against LP.8.1Centers for Disease Control reports LP.8.1, XEC and KP.3.1.1 together constitut ...

2 lineage has been susceptible to pemivibart even if untested due to the consistent structural integrity of the pemivibart epitope. Therefore, Invivyd does not anticipate any meaningful change to ...

Add a description, image, and links to the epitope-prediction topic page so that developers can more easily learn about it.

Department of Pharmaceutical Sciences, College of Pharmacy, University of Michigan, Ann Arbor, Michigan 48109, United States ...

Nanobodies have emerged as a versatile class of biologics with promising therapeutic applications, driving the need for robust tools to predict their epitopes, a critical step for in silico affinity ...

Abstract: T cell receptors (TCRs) play a crucial role in numerous immunotherapies targeting tumor cells. However, their acquisition and optimization present significant challenges, involving laborious ...

Mice were randomly allocated into the treatment arm. Mice were divided into the following six treatment groups: 1) no treatment; 2) long multi-epitope peptide vaccine; 3) long multi-epitope peptide ...

In the published article, there were two errors in the Graphical Abstract as published. In the top right-hand corner of the image, under the “CD8 + T cell” section, “CD4” should read “CD8” and on the ...